绿叶制药(02186.HK)授出三款抗精神病药商业化权利

阿斯达克财经

2025/12/28

绿叶制药(02186.HK) 公布，若干附属与江苏恩华药业股份附属恩华和信签署合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此，恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2594224602"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594224602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594224602?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","is_english":false,"pubTime":"2025-12-28 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594224602","market":"other","top_or_hot":-1,"title":"绿叶制药(02186.HK)授出三款抗精神病药商业化权利","media":"阿斯达克财经","content":"<div>\n<p>绿叶制药(02186.HK) 公布，若干附属与江苏恩华药业股份附属恩华和信签署合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此，恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1492438/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>绿叶制药(02186.HK)授出三款抗精神病药商业化权利</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n绿叶制药(02186.HK)授出三款抗精神病药商业化权利\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-28 17:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1492438/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>绿叶制药(02186.HK) 公布，若干附属与江苏恩华药业股份附属恩华和信签署合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此，恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1492438/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1492438/latest-news/AAFN","article_id":"2594224602","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1492438/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594224602","pubTimestamp":1766915100,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"绿叶制药(02186.HK) 公布，若干附属与江苏恩华药业股份附属恩华和信签署合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此，恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1606":"中医药概念","02186":"绿叶制药"},"translate_title":"Luye Pharma (02186. HK) grants commercialization rights for three antipsychotics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1.5},"content_text":"绿叶制药(02186.HK) 公布，若干附属与江苏恩华药业股份附属恩华和信签署合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此，恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}